» Articles » PMID: 38343612

Hepatocellular Carcinoma Incidence and Mortality in the USA by Sex, Age, and Race: A Nationwide Analysis of Two Decades

Overview
Specialty Gastroenterology
Date 2024 Feb 12
PMID 38343612
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Aims: While the incidence rates of hepatocellular carcinoma (HCC) are increasing, there are limited comprehensive data on demographic-specific incidence and mortality trends in the USA. We aimed to evaluate recent trends in HCC incidence and mortality among different demographic groups in the USA.

Methods: Age-adjusted HCC incidence rates were calculated from the Centers for Disease Control's United States Cancer Statistics database, which combines incidence data on newly diagnosed cancer cases and covers approximately 98% of the population in the USA. Additionally, age-adjusted HCC mortality rates were obtained from the Centers for Disease Control's National Center for Health Statistics database, which offers comprehensive coverage spanning nearly 100% of deaths attributed to HCC in the USA. Rates were stratified by sex, age (older [≥55 years] and younger [<55 years] adults), race and ethnicity (Non-Hispanic White, Non-Hispanic Black, Hispanic, Non-Hispanic Asian/Pacific Islander, and Non-Hispanic American Indian/Alaska Native), and tumor stage at diagnosis (early and late). Annual and average annual percentage change (AAPC) were calculated using joinpoint regression. A sex-specific pairwise comparison was conducted.

Results: Between 2001 and 2020, there were 467,346 patients diagnosed with HCC (26.0% women), with increasing incidence in both sexes without significant difference (=0.65). In younger adults (78,169 patients), the incidence decreased in men but not in women (AAPC difference=-2.39, =0.002). This was seen in various racial and ethnic groups, mostly driven by early-stage tumors (AAPC difference=-2.65, =0.02). There were 329,973 deaths attributed to HCC between 2000 and 2020 (28.4% women). In younger adults (43,093 deaths), mortality decreased in men at a greater rate than in women (AAPC difference=1.61, =0.007). This was seen in various racial and ethnic groups, most notably in non-Hispanic American Indian/Alaska Natives (AAPC difference=-4.51, =0.01).

Conclusions: Nationwide USA data, covering nearly all HCC cases, show an increasing incidence and mortality over the last two decades. In younger adults, there was a decreasing incidence in men but not in women, due to early-stage tumors. Mortality improved in younger men at a greater rate than in women, especially in Non-Hispanic American Indian/Alaska Natives. Future studies are warranted to identify the risk factors associated with the occurrence and outcomes of HCC in demographic-specific populations, especially younger women.

Citing Articles

Association of Statin, Metformin, and Aspirin Use With Hepatocellular Carcinoma in the Research Program.

Almazan E, Chung R Gastro Hep Adv. 2025; 4(1):100535.

PMID: 39758847 PMC: 11699276. DOI: 10.1016/j.gastha.2024.08.014.


Hepatocellular carcinoma national burden across different geographical regions in the United States between 2001 and 2020.

Abboud Y, Malhotra R, Maan M, Mathew A, Abboud I, Pan C World J Methodol. 2024; 14(4):95598.

PMID: 39712566 PMC: 11287541. DOI: 10.5662/wjm.v14.i4.95598.


Cost Effectiveness of Tremelimumab Plus Durvalumab for Unresectable Hepatocellular Carcinoma in the USA.

Xiong X, Guo J Pharmacoeconomics. 2024; 43(3):271-282.

PMID: 39546248 DOI: 10.1007/s40273-024-01453-0.


Health disparities in cirrhosis care and liver transplantation.

Goldberg D, Wilder J, Terrault N Nat Rev Gastroenterol Hepatol. 2024; 22(2):98-111.

PMID: 39482363 DOI: 10.1038/s41575-024-01003-1.


Complex Multi-site Stereotactic Body Re-irradiation With CT-Guided Online Adaptive Radiotherapy.

Sievert D, DSouza A, Zhao X, Prusator M, Mazur T, Kim H Cureus. 2024; 16(9):e68559.

PMID: 39364455 PMC: 11449465. DOI: 10.7759/cureus.68559.


References
1.
Kim H, Fay M, Yu B, Barrett M, Feuer E . Comparability of segmented line regression models. Biometrics. 2004; 60(4):1005-14. DOI: 10.1111/j.0006-341X.2004.00256.x. View

2.
Oh J, Abboud Y, Burch M, Gong J, Waters K, Ghaith J . Rising Incidence of Non-Cardia Gastric Cancer among Young Women in the United States, 2000-2018: A Time-Trend Analysis Using the USCS Database. Cancers (Basel). 2023; 15(8). PMC: 10137096. DOI: 10.3390/cancers15082283. View

3.
Kanwal F, Kramer J, Mapakshi S, Natarajan Y, Chayanupatkul M, Richardson P . Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease. Gastroenterology. 2018; 155(6):1828-1837.e2. PMC: 6279617. DOI: 10.1053/j.gastro.2018.08.024. View

4.
Forner A, Reig M, Bruix J . Hepatocellular carcinoma. Lancet. 2018; 391(10127):1301-1314. DOI: 10.1016/S0140-6736(18)30010-2. View

5.
Wu Z, Petrick J, Florio A, Guillemette C, Beane Freeman L, Buring J . Endogenous sex steroid hormones and risk of liver cancer among US men: Results from the Liver Cancer Pooling Project. JHEP Rep. 2023; 5(7):100742. PMC: 10326694. DOI: 10.1016/j.jhepr.2023.100742. View